SG11202005296SA - Combination therapy between anti-progastrin antibody and immunotherapy to treat cancer - Google Patents

Combination therapy between anti-progastrin antibody and immunotherapy to treat cancer

Info

Publication number
SG11202005296SA
SG11202005296SA SG11202005296SA SG11202005296SA SG11202005296SA SG 11202005296S A SG11202005296S A SG 11202005296SA SG 11202005296S A SG11202005296S A SG 11202005296SA SG 11202005296S A SG11202005296S A SG 11202005296SA SG 11202005296S A SG11202005296S A SG 11202005296SA
Authority
SG
Singapore
Prior art keywords
immunotherapy
combination therapy
treat cancer
progastrin antibody
progastrin
Prior art date
Application number
SG11202005296SA
Other languages
English (en)
Inventor
Alexandre Prieur
Original Assignee
Progastrine Et Cancers S A R L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Progastrine Et Cancers S A R L filed Critical Progastrine Et Cancers S A R L
Publication of SG11202005296SA publication Critical patent/SG11202005296SA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507Comprising a combination of two or more separate antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG11202005296SA 2017-12-05 2018-12-05 Combination therapy between anti-progastrin antibody and immunotherapy to treat cancer SG11202005296SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762594755P 2017-12-05 2017-12-05
PCT/EP2018/083651 WO2019110662A1 (en) 2017-12-05 2018-12-05 Combination therapy between anti-progastrin antibody and immunotherapy to treat cancer

Publications (1)

Publication Number Publication Date
SG11202005296SA true SG11202005296SA (en) 2020-07-29

Family

ID=64949216

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202005296SA SG11202005296SA (en) 2017-12-05 2018-12-05 Combination therapy between anti-progastrin antibody and immunotherapy to treat cancer

Country Status (14)

Country Link
US (2) US11046758B2 (zh)
EP (1) EP3720879B1 (zh)
JP (1) JP7104153B2 (zh)
KR (1) KR102461238B1 (zh)
CN (1) CN111670197A (zh)
AU (1) AU2018379320B2 (zh)
CA (1) CA3084687C (zh)
DK (1) DK3720879T3 (zh)
ES (1) ES2920283T3 (zh)
PL (1) PL3720879T3 (zh)
PT (1) PT3720879T (zh)
SG (1) SG11202005296SA (zh)
TW (1) TWI763956B (zh)
WO (1) WO2019110662A1 (zh)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3084687C (en) * 2017-12-05 2024-01-02 Progastrine Et Cancers S.A R.L. Combination therapy between anti-progastrin antibody and immunotherapy to treat cancer
AU2019228339A1 (en) * 2018-02-27 2020-09-10 Ecs-Progastrin Sa Progastrin as a biomarker for immunotherapy
CN111171146B (zh) * 2020-02-20 2022-03-04 西北农林科技大学 抗h9n2亚型禽流感病毒的纳米抗体、制备方法和应用
JP2024520166A (ja) * 2021-06-11 2024-05-21 グアンドン ファポン バイオファーマ インコーポレイテッド 抗pd-1ヒト化抗体又はその抗原結合性断片及びその使用

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
GB8924581D0 (en) 1989-11-01 1989-12-20 Pa Consulting Services Bleaching of hair
AU633698B2 (en) 1990-01-12 1993-02-04 Amgen Fremont Inc. Generation of xenogeneic antibodies
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5546806A (en) 1991-10-17 1996-08-20 Kain; Aron Z. Microwave vector displacement and acceleration transducer
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化b−b10
ZA932522B (en) 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
US5474896A (en) 1992-05-05 1995-12-12 Institut Pasteur Nucleotide sequence encoding the enzyme I-SceI and the uses thereof
US5792632A (en) 1992-05-05 1998-08-11 Institut Pasteur Nucleotide sequence encoding the enzyme I-SceI and the uses thereof
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
EP0752248B1 (en) 1992-11-13 2000-09-27 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
EP1978033A3 (en) 1995-04-27 2008-12-24 Amgen Fremont Inc. Human antibodies derived from immunized xenomice
CA2219486A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5830729A (en) 1996-04-18 1998-11-03 Institut Pasteur I Sce I-induced gene replacement and gene conversion in embryonic stem cells
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
CA2616914C (en) 1996-12-03 2012-05-29 Abgenix, Inc. Egfr-binding antibody
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
CZ294425B6 (cs) 1997-04-14 2005-01-12 Micromet Ag Způsob výroby anti-humánního antigenového receptoru, anti-humánní antigenový receptor, řetězec VH a VL, souprava pro selekci anti-humánních antigenových receptorů a farmaceutická kompozice, obsahující uvedený receptor
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
WO2003025183A2 (en) 2001-09-14 2003-03-27 Cellectis Random integration of a polynucleotide after in vivo linearization
EP1391213A1 (en) 2002-08-21 2004-02-25 Boehringer Ingelheim International GmbH Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents
JP4966006B2 (ja) 2003-01-28 2012-07-04 セレクティス カスタムメイドメガヌクレアーゼおよびその使用
EP1794586B1 (en) 2004-09-22 2013-01-30 Cancer Advances, Inc., Monoclonal antibodies to progastrin
AU2008317354B2 (en) 2007-10-25 2014-04-10 Ospedale San Raffaele S.R.L. Methods and compositions for targeted integration
PT2488551T (pt) * 2009-10-16 2018-10-31 Inst Nat Sante Rech Med Anticorpos monoclonais contra a progastrina e suas utilizações
US9217032B2 (en) 2010-01-08 2015-12-22 Les Laboratoires Servier Methods for treating colorectal cancer
US8900588B2 (en) 2010-01-08 2014-12-02 Les Laboratories Servier Methods for treating breast cancer
SG184092A1 (en) * 2010-03-24 2012-10-30 Biorealites Prophylaxis of colorectal and gastrointestinal cancer
EA028515B1 (ru) 2010-07-26 2017-11-30 Ле Лаборатуар Сервье Способы и композиции для терапии рака печени
JOP20200094A1 (ar) * 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
TWI711463B (zh) 2014-10-29 2020-12-01 美商戊瑞治療有限公司 用於癌症之組合療法
KR102507685B1 (ko) * 2015-12-31 2023-03-08 프로가스트린 에 캔서스 에스.에이 알.엘. 난소암의 검출 및 치료를 위한 조성물 및 방법
BR112018013272A2 (pt) * 2015-12-31 2018-12-11 Progastrine Et Cancers S A R L composições e métodos para detectar e tratar câncer esofágico
BR112018013268A2 (pt) * 2015-12-31 2018-12-11 Progastrine Et Cancers S A R L composições e métodos para detectar e tratar câncer gástrico
ES2926532T3 (es) * 2017-03-30 2022-10-26 Progastrine Et Cancers S A R L Composiciones y métodos para tratar el cáncer de pulmón
KR102317805B1 (ko) * 2017-03-30 2021-10-27 이씨에스-프로가스트린 에스에이 전립선암을 검출하기 위한 조성물 및 방법
JP7469225B2 (ja) * 2017-06-15 2024-04-16 キャンサー アドヴァンシーズ インク. 腫瘍及び癌に対する体液性及び細胞性免疫を誘発するための組成物及び方法
CA3084687C (en) * 2017-12-05 2024-01-02 Progastrine Et Cancers S.A R.L. Combination therapy between anti-progastrin antibody and immunotherapy to treat cancer
AU2019228339A1 (en) * 2018-02-27 2020-09-10 Ecs-Progastrin Sa Progastrin as a biomarker for immunotherapy

Also Published As

Publication number Publication date
US20210324069A1 (en) 2021-10-21
PL3720879T3 (pl) 2022-09-12
CA3084687A1 (en) 2019-06-13
DK3720879T3 (da) 2022-06-20
PT3720879T (pt) 2022-07-13
EP3720879B1 (en) 2022-05-11
JP7104153B2 (ja) 2022-07-20
WO2019110662A1 (en) 2019-06-13
JP2021505576A (ja) 2021-02-18
ES2920283T3 (es) 2022-08-02
KR102461238B1 (ko) 2022-11-01
KR20200118409A (ko) 2020-10-15
CA3084687C (en) 2024-01-02
RU2020121176A3 (zh) 2022-04-27
US20210009680A1 (en) 2021-01-14
CN111670197A (zh) 2020-09-15
US11046758B2 (en) 2021-06-29
EP3720879A1 (en) 2020-10-14
AU2018379320B2 (en) 2023-06-15
TWI763956B (zh) 2022-05-11
TW201927805A (zh) 2019-07-16
AU2018379320A1 (en) 2020-07-02
RU2020121176A (ru) 2022-01-10

Similar Documents

Publication Publication Date Title
IL267803A (en) Methods for treating cancer with anti-tim-3 antibodies
IL262562A (en) Combination of anti-pd-1 antibodies and radiation for cancer therapy
IL268138A (en) Combinations of cabozantinib and atezolizumab for cancer treatment
IL247066A0 (en) Cancer immunotherapy by combining local and systemic immune stimulation
HK1247630A1 (zh) 用於增强癌症治療的效果的組合物和方法
GEP20217317B (en) Combination therapy for the treatment of cancer
IL273196A (en) Claudin 6 antibodies and methods of cancer treatment
HRP20190888T8 (hr) Konjugat antitijela za igf-1r i lijeka i njegova upotreba u liječenju karcinoma
SG11202005296SA (en) Combination therapy between anti-progastrin antibody and immunotherapy to treat cancer
IL248704A0 (en) Combined treatment with immunotherapy and radiotherapy for the treatment of cancers that express her-2
IL275517A (en) Combined methods and treatment of cancer
SG11201707949XA (en) Anti-vegfr2 human antibody for anti-angiogenic and targeted cancer therapy
IL275913A (en) Methods and combined treatment for cancer treatment
IL269121A (en) Usl-311 for use in the treatment of cancer
RS65488B1 (sr) Kombinacija regorafeniba i nivolumaba za lečenje karcinoma
IL274866A (en) Preparations and methods for the treatment of cancer
GB201717004D0 (en) Methods of cancer therapy
GB201711769D0 (en) Methods of cancer therapy
GB201416605D0 (en) Combination therapy to reduce the risk of and to treat cancer